Recalibrating Retinal Immunity: Peptide-Based Strategies for Durable Vision Preservation in Retinitis Pigmentosa

Led by European Wellness scientists Prof. Dato’ Sri Dr. Mike Chan, Prof. Dato’ Sri Dr. Michelle Wong, and Prof. Dr. Dmytro Klokol, in collaboration with top researchers from UC Irvine and GATC Health, this groundbreaking paper presents powerful new insights into how peptide therapeutics could potentially halt – and even reverse – vision loss caused by RP.

What this research reveals:
🔹 RP isn’t just genetic – inflammation, oxidative stress, and immune dysfunction accelerate degeneration.
🔹 Bioactive peptides (like thymosin β4 and KPV) can potentially retrain the immune system and promote retinal repair.
🔹 A breakthrough technique called Antigen Adaptive Selective Immunotherapy (AASI) may potentially stop immune attacks on retinal cells – restoring immune balance without suppressing the whole immune system.
🔹 Next-gen delivery systems are enhancing peptide stability, precision, and efficacy – offering new hope for long-term visual preservation.

This is a huge leap forward in the race to help patients affected by RP – and it opens the door to similar strategies for other neurodegenerative eye diseases. A game-changer in the making!

MORE PUBLICATIONS:
https://european-wellness.eu/publications/